Femtech startup KOVE medical raises CHF1.6M to make fetal surgery safer

What's the deal? KOVE medicalDealroom has a profile for this one. Try Dealroom →, a University of ZurichDealroom has a profile for this one. Try Dealroom → spin-off, has closed a CHF1.6 million ($1.98 million) seed round backed by a syndicate of angel investors. The Swiss femtech startup develops an implantable device that reduces the risk of preterm birth after fetal surgery.

What's the endgame? Fetoscopies — minimally invasive surgeries performed inside the womb — treat life-threatening conditions before birth, but they require perforating the uterine wall and amniotic sac. That weakens the protective membrane and can cause fluid leakage and rupture, often leading to preterm birth.

KOVE's device closes the defect left by surgical instruments at the end of the operation, stabilising the membrane and preventing complications. The aim is to make in-utero interventions safe enough to become a standard method of care.

What's the money for? The company plans to use the funds to reach First-in-Human studies, a key milestone for any medical device seeking regulatory approval.

Why now? "This is a crucial step forward for our company, and we are incredibly grateful for the strong support and trust from our syndicate of visionary angel investors," the company said in a statement on LinkedIn.

The signal: At roughly CHF1.6 million, the round sits toward the lower end of seed financings, reflecting the early, pre-clinical stage of the technology. For femtech and fetal medicine — long underfunded corners of medtech — angel backing at this stage marks an early bet on a market with few standard solutions.

Read more: startupticker.ch

Image credit: Generated with Gemini